Pregabalin influences insula and amygdala activation during anticipation of emotional images

Neuropsychopharmacology

Volumn 36, Issue 7, 2011, Pages 1466-1477

  Aupperle, Robin L ^a,b   Ravindran, Lakshmi ^a,b   Tankersley, Dharol ^a   Flagan, Taru ^a   Stein, Nathan R ^c   Simmons, Alan N ^a,b   Stein, Murray B ^a,b   Paulus, Martin P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

amygdala; anticipation; insula; neuroimaging; pregabalin; psychopharmacology

Indexed keywords

PREGABALIN;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ANTICIPATION; ARTICLE; BRAIN REGION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; EMOTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GUSTATORY CORTEX; HUMAN; INSULA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMYGDALA; ANALGESICS; ATTENTION; BRAIN MAPPING; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PHOTIC STIMULATION; YOUNG ADULT;

EID: 79955986521     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.32     Document Type: Article

References (73)

1. Akerstedt T, Gillberg M (1990). Subjective and objective sleepiness in the active individual. Int J Neurosci 52: 29-37.
2. Anderson AK, Christoff K, Stappen I, Panitz D, Ghahremani DG, Glover G et al (2003). Dissociated neural representations of intensity and valence in human olfaction. Nat Neurosci 6: 196-202. (Pubitemid 36182790)
3. Anderson IM, Del-Ben CM, Mckie S, Richardson P, Williams SR, Elliott R et al (2007). Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. Neuroreport 18: 1351-1355. (Pubitemid 47344320)
4. Arce E, Miller DA, Feinstein JS, Stein MB, Paulus MP (2006). Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. Psychopharmacology (Berl) 189: 105-116. (Pubitemid 44607264)
5. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP (2008). Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl) 196: 661-672.
6. Asnis GM, Hameedi FA, Goddard AW, Potkin SG, Black D, Jameel M et al (2001). Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 103: 1-14. (Pubitemid 32709996)
7. Atack JR (2003). Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord 2: 213-232.
8. Baldwin DS (2008). Room for improvement in the pharmacological treatment of anxiety disorders. Curr Pharm Des 14: 3482-3491.
9. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C et al (2004). Sertraline vs paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 65: 405-413.
10. Brawek B, Loffler M, Dooley DJ, Weyerbrock A, Feuerstein TJ (2008). Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol 376: 301-307.
11. Britton JC, Taylor SF, Sudheimer KD, Liberzon I (2006). Facial expressions and complex IAPS pictures: common and differential networks. Neuroimage 31: 906-919. (Pubitemid 43776660)
12. Christmas D, Hood S, Nutt D (2008). Potential novel anxiolytic drugs. Curr Pharm Des 14: 3534-3546.
13. Cloos JM, Ferreira V (2009). Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 22: 90-95.
14. Cox RW (1996). AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comp Biomed Res 29: 162-173. (Pubitemid 26266657)
15. Craig AD (2009). How do you feelFnow? The anterior insula and human awareness. Nat Rev Neurosci 10: 59-70.
16. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE (2009). What is an anxiety disorder? Depress Anxiety 26: 1066-1085.
17. Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ (2004). Neural systems supporting interoceptive awareness. Nat Neu-rosci 7: 189-195. (Pubitemid 38129796)
18. Davidson JR, Bose A, Korotzer A, Zheng H (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19: 234-240. (Pubitemid 39014143)
19. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R et al (1993). Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13: 423-428. (Pubitemid 24026104)
20. Davis M, Whalen PJ (2001). The amygdala: vigilance and emotion. Mol Psychiatry 6: 13-34. (Pubitemid 32096061)
21. Del-Ben CM, Deakin JF, Mckie S, Delvai NA, Williams SR, Elliott R et al (2005). The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 30: 1724-1734. (Pubitemid 43090698)
22. Dooley DJ, Taylor CP, Donevan S, Feltner D (2007). Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 28: 75-82. (Pubitemid 46161838)
23. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23: 18-28. (Pubitemid 350294866)
24. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD et al (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psycho-pharmacol 23: 240-249. (Pubitemid 36807791)
25. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H et al (2002). Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neurophar-macology 42: 229-236. (Pubitemid 34137026)
26. Floyd TF, Ratcliffe SJ, Wang J, Resch B, Detre JA (2003). Precision of the CASL-perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories. J Magn Reson Imag 18: 649-655. (Pubitemid 37467265)
27. Fusar-Poli P, Placentino A, Carletti F, Landi P, Allen P, Surguladze S et al (2009). Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 34: 418-432.
28. Garavan H, Pendergrass JC, Ross TJ, Stein EA, Risinger RC (2001). Amygdala response to both positively and negatively valenced stimuli. Neuroreport 12: 2779-2783. (Pubitemid 32803217)
29. Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN (1996). The novel anticonvulsant drug, gabapentin (neurontin), binds to alpha-2-delta subunit of a calcium channel. J Biol Chem 271: 5768-5776. (Pubitemid 26083915)
30. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM (2006). Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59: 816-820.
31. Hill MN, Gorzalka BB (2009). The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 8: 451-458.
32. Hindmarch I, Trick L, Ridout F (2005). A double-blind, placebo-and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 183: 133-143. (Pubitemid 41609265)
33. Hoffman EJ, Mathew SJ (2008). Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 75: 248-262.
34. Jorstad-Stein EC, Heimberg RG (2009). Social phobia: an update on treatment. Psychiatr Clin North Am 32: 641-663.
35. Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186: 222-226. (Pubitemid 40343816)
36. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627. (Pubitemid 40973437)
37. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S (1998). Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharma-cology (Berl) 136: 357-366. (Pubitemid 28189665)
38. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L et al (2000). Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 10: 120-131. (Pubitemid 30456920)
39. Lang PJ, Bradley MM, Cuthbert BN (2008). International Affective Picture System (IAPS): Affective Ratings of Pictures and Instruction Manual. Technical Report A-8. University of Florida: Gainesville, FL.
40. Lewis PA, Critchley HD, Rotshtein P, Dolan RJ (2007). Neural correlates of processing valence and arousal in affective words. Cereb Cortex 17: 742-748.
41. Lovero KL, Simmons AN, Aron JL, Paulus MP (2009). Anterior insular cortex anticipates impending stimulus significance. Neuroimage 45: 976-983.
42. Lydiard RB, Rickels K, Herman B, Feltner DE (2010). Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 13: 229-241.
43. McIntosh A, Cohen A, Turnbull N, Esmonde L, Dennis P, Eatock J et al (2004). Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. In: National Collaborating Center for Primary Care. University of Sheffield/ London: Sheffield.
44. Mitte K, Noack P, Steil R, Hautzinger M (2005). A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25: 141-150. (Pubitemid 40395092)
45. Moroz G, Rosenbaum JF (1999). Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 60: 604-612. (Pubitemid 29451557)
46. Morrison SE, Salzman CD (2010). Re-valuing the amygdala. Curr Opin Neurobiol 20: 221-230.
47. Nitschke JB, Sarinopoulos I, Mackiewicz KL, Schaefer HS, Davidson RJ (2006). Functional neuroanatomy of aversion and its anticipation. Neuroimage 29: 106-116. (Pubitemid 41828035)
48. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R et al (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160: 533-540. (Pubitemid 41094262)
49. Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB et al (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24: 141-149. (Pubitemid 38380837)
50. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB (2005). Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62: 282-288. (Pubitemid 40990973)
51. Paulus MP, Stein MB (2007). Role of functional magnetic resonance imaging in drug discovery. Neuropsychol Rev 17: 179-188. (Pubitemid 46889565)
52. Phillips ML, Drevets WC, Rauch SL, Lane R (2003). Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biol Psychiatry 54: 504-514. (Pubitemid 37289437)
53. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID vs TID dosing. J Clin Psychopharmacol 25: 151-158. (Pubitemid 40395093)
54. Pull CB, Damsa C (2008). Pharmacotherapy of panic disorder. Neuropsychiatr Dis Treat 4: 779-795.
55. Rack-Gomer AL, Liau J, Liu TT (2009). Caffeine reduces resting-state BOLD functional connectivity in the motor cortex. Neuroimage 46: 56-63.
56. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ et al (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62: 1022-1030. (Pubitemid 41248382)
57. Rosen JB (2004). The neurobiology of conditioned and unconditioned fear: a neurobehavioral system analysis of the amygdala. Behav Cogn Neurosci Rev 3: 23-41.
58. Salinsky M, Storzbach D, Munoz S (2010). Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 74: 755-761.
59. Simmons A, Matthews SC, Stein MB, Paulus MP (2004). Anticipation of emotionally aversive visual stimuli activates right insula. Neuroreport 15: 2261-2265. (Pubitemid 39392252)
60. Simmons A, Strigo I, Matthews SC, Paulus MP, Stein MB (2006). Anticipation of aversive visual stimuli is associated with increased insula activation in anxiety-prone subjects. Biol Psychiatry 60: 402-409. (Pubitemid 44215851)
61. Simmons AN, Arce E, Lovero KL, Stein MB, Paulus MP (2009). Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsycho-pharmacol 12: 1009-1020.
62. Simmons AN, Paulus MP, Thorp SR, Matthews SC, Norman SB, Stein MB (2008). Functional activation and neural networks in women with posttraumatic stress disorder related to intimate partner violence. Biol Psychiatry 64: 681-690.
63. Small DM, Gregory MD, Mak YE, Gitelman D, Mesulam MM, Parrish T (2003). Dissociation of neural representation of intensity and affective valuation in human gustation. Neuron 39: 701-711. (Pubitemid 36993586)
64. Spielberger C (1983). Manual for the State-Trait Anxiety Inventory In: Consulting Psychologists Press: Palo Alto, CA.
65. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156: 756-760. (Pubitemid 29220075)
66. Strigo IA, Matthews SC, Simmons AN (2010a). Right anterior insula hypoactivity during anticipation of homeostatic shifts in major depressive disorder. Psychosom Med 72: 316-323.
67. Strigo IA, Simmons AN, Matthews SC, Craig AD (2010b). The relationship between amygdala activation and passive exposure time to an aversive cue during a continuous performance task. PLoS One 5: e15093.
68. Takahashi H, Yahata N, Koeda M, Takano A, Asai K, Suhara T et al (2005). Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage 27: 991-1001. (Pubitemid 41317266)
69. Van Ameringen M., Mancini C, Patterson B, Simpson W (2009). Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci 46: 53-61.
70. Vaswani M, Linda FK, Ramesh S (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27: 85-102. (Pubitemid 36131110)
71. Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U et al (2010). Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 49: 1161-1170.
72. Wise RG, Lujan BJ, Schweinhardt P, Peskett GD, Rogers R, Tracey I (2007). The anxiolytic effects of midazolam during anticipation to pain revealed using fMRI. Magn Reson Imag 25: 801-810. (Pubitemid 47081367)
73. Wong EC, Buxton RB, Frank LR (1998). Quantitative imaging of perfusion using a single subtraction (QUIPSS and QUIPSS II). Magn Reson Med 39: 702-708. (Pubitemid 28189141)